anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND & AIMS: The international cancer cachexia criteria with a cutoff of 5% weight loss (WL) was proposed in Western patients. The Asian Working Group for Cachexia (AWGC) developed new criteria in Asian patients. The AWGC criteria are not cancer-specific and employ a cutoff of 2% WL. However, it is unclear whether both criteria are useful in patients with very advanced cancer because WL can be underestimated owing to fluid retention. Therefore, this study aimed to investigate the impacts of fluid retention on the prognostic abilities of both criteria in cancer patients with weeks of survival.
METHODS: This study involved a secondary analysis of a prospective cohort study. The inclusion criteria constrained the study to adult patients with advanced cancer. Patients were divided into Non-cachexia and Cachexia groups using the international criteria and AWGC criteria. We performed time-to-event analyses using the Kaplan-Meier method and log-rank tests, and by conducting univariate and multivariate Cox regression analyses.
RESULTS: A total of 402 patients were included in the analysis. Using the international criteria, the p-values for the log-rank test and stratified log-rank test for the mixed patients with and without fluid retention were 0.55 and 0.18, respectively. Using the AWGC criteria, the p-values for the log-rank test and stratified log-rank test for the mixed patients with and without fluid retention were 0.38 and 0.12, respectively. Without considering the impacts of fluid retention, no significant differences were observed between the Non-cachexia and Cachexia groups for both criteria. After adjusting for the status of fluid retention, significantly higher risks of mortality were not observed in the Cox proportional hazard model for the Cachexia group compared with the Non-cachexia group, for both criteria. However, significant associations were observed between fluid retention and overall survival.
CONCLUSIONS: The international criteria and AWGC criteria lost their prognostic abilities in cancer patients with weeks of survival. Since measurements of %WL were significantly confounded by fluid retention, fluid retention-adjusted criteria for cachexia need to be developed for cancer patients with refractory cachexia.
The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations.

In neonates or in very small infants even small volumes of fluid may affect fluid and electrolyte balance. Care must be exercised in treatment of neonates, especially pre-term neonates, whose renal function may be immature and whose ability to excrete fluid and solute loads may be limited. Fluid intake, urine output, and serum electrolytes should be monitored closely.

In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.

Serum glucose concentrations should be frequently monitored when dextrose is prescribed to pediatric patients, particularly infants, neonates, and low birth weight infants. See WARNINGS and DOSAGE AND ADMINISTRATION.
The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. After the researcher is sure that there are no contraindications in the application of the gel pad, dry cold will be applied to the determined area with the gel pad for 3 minutes.
FIELD: medicine, oncology. SUBSTANCE: invention relates to the improved systems of directed tumor therapy using enzyme and prodrug compound, in part, antibody-mediated therapy using enzyme and prodrug (ADEPT). Enzyme using in the system presents a mutated form of enzyme of the host cell where natural enzyme of the host cell, for example, ribonuclease disposes its natural substrate by means of interaction of ions pair. This interaction of mutated enzyme and prodrug compound in the system is a reverse one (i. e. the reverse polarity). EFFECT: expanded arsenal of antitumor agents. 20 cl, 33 dwg
After giving their informed consent, the study subjects will complete screening procedures to assess their eligibility for the study (Visit 1). Participants deemed suitable for the study will be randomized into two study arms (placebo, probiotic) before undergoing a baseline visit (Visit 2) before the start of the intervention period. During the 6-month intervention period, the participants will attend study visits at 3 months (Visit 3) into the intervention as well as at the end of intervention (at 6 months, Visit 4). Blood, saliva, and faecal samples will be collected at visits 2-4. In addition to sampling, during the whole intervention period, the participants will fill out a weekly questionnaire in which they are asked to record any possible symptoms of COVID-19. The participants' dietary habits are assessed via a food frequency questionnaire (FFQ) before the start of the intervention period. Also, the participants are asked to maintain their habitual diet and lifestyle as well as not to consume any other probiotic or prebiotic supplements.
PURPOSE:To allow the selective adsorption away of a contrast medium without removing useful materials, such as albumin and immune globulin by constituting the contrast medium adsorber of a water-insoluble porous body having a carbide surface. CONSTITUTION:A cap 6 having a bodily fluid introducing port 5 is screwed via a packing 4 extended with a filter 3 on the inner side to the aperture at one end of a cylinder 2 of an adsorbing device 1. A gap 8 having a bodily fluid leading out port 7 is screwed via a packing 4' extended with a filter 3' on the inner side to an aperture at the other end of the cylinder 2 to form a container. The contrast medium adsorber consisting of the water-insoluble porous body having the carbide surface, such as spherical active carbon of a petroleum pitch system, is packed and held between the filters 3 and 3' to form an adsorber chamber 9. The blood taken out of the inside of the body is directly passed through the adsorbing device 1 and is thereby purified. The contrast medium in the bodily fluid is selectively adsorbed away at a high rate in this way.
PURPOSE:A monoclonal antibody, obtained by transmigrating together with an intranuclear nonhistone protein high mobility group (HMG-1) from a cytoplasm to a nuleus and useful as a diagnostic agent for living bodies. CONSTITUTION:An intranuclear nonhistone protein high mobility group-1 (HMG-1) derived from a human tissue, etc., is administered to a mouse, etc., and immunized to give cells capable of producing an antibody, e.g. lymphocyte, etc. The resultant cells in an amount of 5-20 times based on myelomatous cells, e.g. SP2/o-Ag14, etc., are then added to the myelomatous cells and subjected to cell fusion in the presence of polyethylene glycol. The resultant hybridoma is further cloned in an agar culture medium, etc., to afford a monoclonal antibody, which is then multiplied in a mammalian abdominal cavity or culture medium to produce an anti HMG-1 antibody. The resultant antibody is then separated and recovered to provide the aimed monoclonal antibody against the intranuclear nonhistone protein.
BACKGROUND: Laparoscopic emergent inguinal hernia repair remains controversial despite studies suggesting it is safe and feasible. Variables associated with laparoscopic compared with open emergent inguinal hernia repair are currently not well described. This study aims to investigate patient characteristics and risk factors associated with laparoscopic emergent inguinal hernia repair.
METHODS: The American College of Surgeons National Surgical Quality Improvement database was queried for adult patients (age ≥18 years) who had undergone emergent inguinal hernia repair between 2015 and 2021. The relationships between demographic variables and laparoscopic compared with open emergent inguinal hernia repair were evaluated using univariate and multivariate analyses.
RESULTS: A total of 8,215 patients were included in this analysis. Use of laparoscopic emergent inguinal hernia repair increased from 9% in 2015 to 23% in 2021. Female patients (odds ratio, 1.84, P < .001) and patients aged ≤65 years (odds ratio, 1.25, P = .005) were more likely to undergo laparoscopic repair. Black (odds ratio, 0.73, P = .003) and Hispanic (odds ratio, 0.72, P = .006) patients and patients with greater American Society of Anesthesiologists classification (odds ratio, 0.86, P = .037), ascites (odds ratio, 0.39, P = .039), and preoperative dialysis requirement (odds ratio, 0.45, P = .017) were less likely to undergo laparoscopic repair. Aside from a decreased likelihood of readmission in patients who underwent laparoscopic surgery (odds ratio, 0.696, P = .024), there was no difference in other postoperative outcomes, despite a laparoscopic approach being associated with greater rates of concomitant procedures compared with an open approach (24% vs 18%, P < .001).
CONCLUSIONS: Female sex, younger age, and lower American Society of Anesthesiologists class were associated with a greater likelihood of laparoscopic surgery. Black and Hispanic patients and patients with ascites and dialysis requirements were less likely to undergo laparoscopic repair. Laparoscopic inguinal hernia repair can be safely performed in an emergent setting.
PURPOSE:To obtain a new compound excellent in water solubility, having antiallergic activity, anti-inflammatory activity and antioxidizing activity, etc., thus useful for preventing or treating allergic diseases, inflammatory diseases, cataract and ischemic organopathy. CONSTITUTION:The objective compound is expressed by formula I (R is H, OH, methyl or methylene; however, when there is OH at the 17-site of the steroid skeleton, or when R is OH, also including the acylated form or ketone form of the steroid skeleton, respectively) or a salt thereof, e.g. 21-(L-ascorbic acid-2-phosphoryl)dexamethasone sodium salt. This compound of formula I can be obtained by condensation reaction between an adrenocortical steroid of formula II and ascorbic acid-2-phosphoric ester of formula III in the presence of a dehydrating condensation agent (pref. N,N'-dicyclohexylcarbodiimide) in a solvent (pref. pyridine) at room temperature for 1-5hr.
Within 30 days after extracting bone marrow, autologous bone marrow-derived mesenchymal stem cells is directly injected into the lesion. Then the second cell is injected within 30 days after the first cell injection.
Ultrasound-guided brachial plexus nerve block. A total of 30 ml of lidocaine (10 mg/ml) with adrenaline (5 ug/ml) will be administered in multiple injections.
Patients randomized to this group will listen daily to a musical playlist for 30 - 60 minutes in a row through a mobile device. This will be performed in addition to the opioid treatment.
Transient hypotension following rapid intravenous administration has been reported in 1% to 2% of patients. It has not been associated with cardiac toxicity or electrocardiographic changes. No delayed hypotension has been noted. To prevent this rare occurrence, it is recommended that etoposide be administered by slow intravenous infusion over a 30- to 60-minute period. If hypotension occurs, it usually responds to cessation of the infusion administration of fluids or other supportive therapy as appropriate. When restarting the infusion, a slower administration rate should be used.
The invention relates to a method for preparing a phenylpropanoid with hypolipidemic activity from rhaponticum carthamoides (willd.) iijin. According to the method, the new phenylpropanoid compound represented by the following formula 1 is prepared from compositae rhaponticum carthamoides (willd.) iijin as raw material. The phenylpropanoid has the hypolipidemic effect, can reduce triglyceride, total cholesterol and low-density lipoprotein, and also has the obvious effect on increasing the high/low density lipoprotein ratio. The phenylpropanoid can be fast prepared with constant quality by combining solvent extraction with column chromatography purification. The preparation method has the advantages of low cost and simple operation, and the product has high purity and is suitable for being used as a standard substance and for drug development.
This study will be conducted as a randomized controlled experimental study to determine the effect of nursing process teaching in the metaverse environment on the instructional materials motivation and academic achievement of nursing students. The nursing process course will be conducted in a metaverse environment. A virtual classroom is designed in the metaverse space for the execution of this course. This study will be conducted from March 2023 to April 2023 in the nursing department of a university. The sample consisted of 42 students who volunteered to participate in the research and met the inclusion criteria. Scales and Forms to be used in the Study; Personal Information Form, The Instructional Materials Motivation Scale, and Academic Success Assessment (Quiz). With the simple randomization method, students will be assigned to the experimental and control groups. But students will not know which group is the experimental group.
The introduction of a deflated catheter (Foley catheter nº 16F) through the outer cervix orifice is preceded by iodine disinfection of the cervix. The intracervical catheter is distended with 40mL of a saline solution. The end of the catheter is taped to the medial portion of the thigh and manual traction is applied to the catheter every 6 hours. If it is not spontaneously extruded it is removed after 24h. Cervix priming occurs in an inpatient setting.
After laparoscopic surgery, the pain levels of the patients were evaluated and appropriate shoulder massage was applied to the patients 2 times at 6 st intervals and the pain levels of the patients were evaluated again. On the morning of the 1st postoperative day, the sleep quality of the patients was evaluated with the Richard Campbell Sleep Scale.
PURPOSE: To obtain a medicine having a cell protecting activity, etc., and useful for alimentary canal ulcer of a mammal including a human by including a specific compound, a carrier and an excipient. CONSTITUTION: This medicine contains at least one kind of compound expressed by the formula  (n) is 0 to 2; R is H, an alkali, etc.}, at least one kind of pharmaceutical carrier (e.g. water, gelatin, lactose, starch, etc.) and/or another excipient as an active component. Furthermore, at least one kind of well-known active component not having a synergism in a prescribed combination is contained as the active component. The compound of the formula is mixed with the well-known active component and the resultant mixture is transformed into a medical formulation material to obtain a medicine. The compound of the formula and the medicine containing the compound are used in the amounts sufficient to obtain a desired curing or preventing effect.
The present application discloses compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals, e.g. cows, i.a. a composition comprising phosphate-binder(s) for use in the prophylactic treatment of parturient hypocalcemia in a ruminant animal, e.g. a cow, and e.g. wherein the composition is unit dosage form(s), and wherein one or more dosages per day of the unit dosage form(s) of the composition are manually administered to the gastrointestinal tract of the ruminant animal, or wherein the composition is presented in wet form. The application also discloses a composition comprising one or more phosphate-binders and one or more nutrients selected from minerals, vitamins and amino acids, and a composition comprising an inhibitor of the small intestinal Na-phosphate transporter for use in the prophylactic treatment of parturient hypocalcemia in a ruminant animal like a cow. Phosphate-binders are selected from aluminium, iron, sevelamer, and lanthanum salts with inorganic or organic acids, a hydrate thereof or any mixture thereof.
A process for preventing trace element deficiency in animals and injectable compositions are described. The trace element compounds are put in suspension in an oil, such as purified olive oil. The said compounds are in an insoluble, non ionizable form, which is solubilized slowly by a moderate inflammatory reaction. In the case of copper, a suitable form is powdered copper or copper oxide. For zinc, zinc oxide or zinc is used. For manganese, the oxide Mn3O4 is prefered. The compositions are administered to ovines, or bovines by intramuscular or subcutaneous injections.
A total of 50 subjects in this group in this group received Poly ADP-ribose Polymerase (PARP) Inhibitor along with ADT mentioned above. Enrolled patients carry homologous recombination repair (HRR) gene mutation verified by molecular testing. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
PURPOSE OF REVIEW: The purpose of this review is to provide a background of osteoporosis and air pollution, discussing increasing incidence of the disease with exposure to pollutants and the role that inflammation may play in this process.
RECENT FINDINGS: Osteoporosis-related fractures are one of the most pressing challenges for the ageing global population, with significant increases in mortality known to occur after major osteoporotic fractures in the elderly population. Recent studies have established a firm correlative link between areas of high air pollution and increased risk of osteoporosis, particularly alarming given the increasingly urban global population. While the culprit pollutants and molecular mechanisms underlying this phenomenon have not yet been elucidated, initial studies suggest a role for inflammatory cascades in this phenomenon. While much more research is required to identify the most damaging air pollutants and to delineate the specific inflammatory molecular mechanisms, it is clear from the literature that shedding light on these pathways would unveil potential therapeutic targets to treat bone diseases, including osteoporosis. Major deficiencies of current animal models highlight the need for complex human in vitro models such as organ-on-a-chip technology to better understand the impact of air pollution.
Naltrexone implants must be administered by a physician.

To prevent occurrence of an acute abstinence syndrome (withdrawal) in patients dependent on opioids, or exacerbation of a pre-existing subclinical abstinence syndrome, opioid-dependent patients, including those being treated for alcohol dependence, must be opioid-free for a minimum of 7–10 days before starting Naltrexone Implant treatment. Since the absence of an opioid drug in the urine is often not sufficient proof that a patient is opioid-free, a naloxone challenge test should be employed if the prescribing physician feels there is a risk of precipitating a withdrawal reaction following administration of Naltrexone Implants. Patients treated for alcohol dependence with Naltrexone Implants should be assessed for underlying opioid dependence and for any recent use of opioids prior to initiation of treatment with Naltrexone Implants. Precipitated opioid withdrawal has been observed in alcohol-dependent patients in circumstances where the prescriber had been unaware of the additional use of opioids or dependence on opioids.

The aluminum (back) part of the blister packs should be wiped with sterile 70% isopropyl alcohol pads prior to opening. Implants should be handled via aseptic technique and should be used immediately.

The recommended dose of Naltrexone implants is 1200mg delivered subcutaneously every 10-12 weeks.

Reemergence of cravings should be screened and may be used as a gauge for the need for re-implantation schedule.

Healthcare providers should tailor the length of treatment to individual patients. Naltrexone has been administered to patients who are alcohol dependent for 6 months to 1 year with no additional safety concerns. Many scientists claim that treatment duration should last at least 1 year since this is the amount of time it can take to change the brain’s addiction pathways.

Treatment with Naltrexone should be part of a psychological and psychosocial program.
Travoprost, latanoprost and bimatoprost, ophthalmic solution are topical medications used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. they are synthetic prostaglandin F 2α analogue (and prodrug for bimatoprost) that works by increasing the outflow of aqueous fluid from the eyes.
The present invention relates to a foot health-care medicine which is a medicinal preparation made from raw materials of spanishneedles herb, hairyvein agrimonia herd, corydalis tuber, doubleteeth pubesscent angelica root, twotoothed achyranthes root, coffonrose hibiscus leaf, obscured homalomena rhizome, dahuria angelica root, fineleaf schizonepeta herb, paniculate swallowwort root, cortex erythrinae, etc. according to certain proportion. The patent medicine of the present invention contains various ingredients of alkaloid, amino acid, vitamins, plant hormones, etc. The medicine of the present invention can be used for feet through external application to obtain the pharmacological functions of dredging channels and collaterals, harmonizing qi and blood, removing toxicity substances, expelling blood stasis, eliminating swellings, removing pain, sterilizing, relieving itching, etc. during activities which are in need of using feet for long time, such as long-distance walk, physical exercise, military training, etc. The medicine is used for the feet of users to make the users comfortable, untired and non achy, and the staying power of the activities is simultaneously enhanced. The medicine of the present invention can be used for rapidly dispersing the swellings, removing the pain and relieving the fatigue of the feet after the activities, and can be also used for relieving the discomfort of persons in middle and old age, such as the qi and blood stasis of the feet, leg and foot numbness, etc. The health-care curative effects of the present invention are obvious, and the effective rate can reach 96.29%, and the foot diseases of achilles tendinitis, beriberi, eczema, etc. can be effectively prevented and treated after the foot health-care medicine of the present invention is used frequently.